Business Description
Affymax, Inc.
NAICS : 325412
SIC : 2834
ISIN : US00826A1097
Description
Affymax Inc is a development-stage biopharmaceutical company, engaged in developing novel peptide-based therapeutics for the treatment of life-threatening conditions. The company's product includes OMONTYS, an injection for the treatment of anemia due to chronic kidney disease in adult patients on dialysis. OMONTYS is a synthetic, peptide-based erythropoiesis stimulating agent, or ESA, designed to stimulate the production of red blood cells and has been the only once-monthly ESA available to the adult dialysis patient population in the U.S.
Financial Strength
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Cash-To-Debt | No Debt | |||||
| Equity-to-Asset | -0.19 | |||||
| Interest Coverage | No Debt | |||||
| Piotroski F-Score | 3/9 | |||||
| Altman Z-Score | -111.67 | |||||
| Beneish M-Score | 25.22 | |||||
| WACC vs ROIC | ||||||
Growth Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Revenue Growth Rate | -79.4 | |||||
| 3-Year EBITDA Growth Rate | -7.5 | |||||
| 3-Year EPS without NRI Growth Rate | -11.9 |
Momentum Rank
| Name | Current | Vs Industry | Vs History |
|---|
Liquidity Ratio
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Current Ratio | 0.71 | |||||
| Quick Ratio | 0.71 |
Dividend & Buy Back
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| 3-Year Average Share Buyback Ratio | -15.2 |
Profitability Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| Gross Margin % | 100 | |||||
| Operating Margin % | -12128.57 | |||||
| Net Margin % | 7300 | |||||
| FCF Margin % | -19996.77 | |||||
| ROE % | -420.95 | |||||
| ROA % | 123.58 | |||||
| ROC (Joel Greenblatt) % | -1007.51 |
GF Value Rank
| Name | Current | Vs Industry | Vs History | |||
|---|---|---|---|---|---|---|
| PS Ratio | 2 | |||||
| Price-to-Tangible-Book | 0.93 | |||||
| EV-to-EBIT | 0.17 | |||||
| EV-to-EBITDA | 0.18 | |||||
| Price-to-Net-Current-Asset-Value | 1.19 | |||||
| Price-to-Net-Cash | 1.64 | |||||
| Earnings Yield (Greenblatt) % | 588.2 | |||||
| FCF Yield % | -44031.58 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsPeter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Affymax, Inc. Executives
DetailsGF Value
Analyst Estimate
Key Statistics
| Name | Value | ||
|---|---|---|---|
| Revenue (TTM) (Mil €) | 0.031 | ||
| EPS (TTM) (€) | 0 | ||
| Beta | 0 | ||
| Volatility % | 0 | ||
| 14-Day RSI | 0 | ||
| 14-Day ATR (€) | 0 | ||
| 20-Day SMA (€) | 0 | ||
| 12-1 Month Momentum % | 0 | ||
| 52-Week Range (€) | 0.09 - 1.76 | ||
| Shares Outstanding (Mil) |
Piotroski F-Score Details
Year:
| Component | Result | ||
|---|---|---|---|
| Piotroski F-Score | 3 | ||
| Positive ROA | |||
| Positive CFROA | |||
| Higher ROA yoy | |||
| CFROA > ROA | |||
| Lower Leverage yoy | |||
| Higher Current Ratio yoy | |||
| Less Shares Outstanding yoy | |||
| Higher Gross Margin yoy | |||
| Higher Asset Turnover yoy |
Affymax, Inc. Filings
| Filing Date | Document Date | Form | ||
|---|---|---|---|---|
| No Filing Data | ||||
Affymax, Inc. Stock Events
| Event | Date | Price(€) | ||
|---|---|---|---|---|
| No Event Data | ||||
Affymax, Inc. Frequently Asked Questions
What is Affymax, Inc.(FRA:A5Y)'s stock price today?
The current price of FRA:A5Y is €0.82. The 52 week high of FRA:A5Y is €1.76 and 52 week low is €0.09.
When is next earnings date of Affymax, Inc.(FRA:A5Y)?
The next earnings date of Affymax, Inc.(FRA:A5Y) is .
Does Affymax, Inc.(FRA:A5Y) pay dividends? If so, how much?
Affymax, Inc.(FRA:A5Y) does not pay dividend.
Press Release
| Subject | Date | |||
|---|---|---|---|---|
| No Press Release | ||||
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers